title: [Endocrinology].
abstract: Treatment and follow-up of differenciated thyroid carcinoma and use of recombinant human TSH in the case of ablative radio-iodine treatment or thyroglobulin stimulation are discussed in the context of new international recommandations. Subclinical thyroid disease and abnormal thyroid function tests during pregnancy are the other topics. Treatment of subclinical hyperthyroidism is recommended when TSH is below 0.1 mU/l because of cardiac and bone complication while a substitutive thyroid hormone therapy is proposed when TSH is above 10 mU/l in subclinical hypothyroidism. During pregnancy, T4 replacement is recommended in women with subclinical and overt hypothyroidism because of adverse outcome for either the fetus or the mother. By contrast, treatment should be initiated only in over hyperthyroidism with propylthiouracil as a first-line drug.
authors.affiliation: Service d'endocrinologie, diabétologie et nutrition, HUG, Genève. Patrick.Meyer@hcuge.ch
authors.forename: P
authors.initials: P
authors.lastname: Meyer
mesh_terms: D006801:Humans; D013959:Thyroid Diseases / Q000188:drug therapy*; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D013972:Thyrotropin / Q000627:therapeutic use*
chemical_list: D013972:Thyrotropin